Volition appoints Dr Andrew Retter as Chief Medical Officer [Yahoo! Finance]
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: Yahoo! Finance
Dr Retter will provide medical leadership at Volition and ensure the company's scientific and clinical efforts are aligned with patient needs. Andrew is an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust in London , where he has worked as a Consultant since 2014 and leads Clinical Governance in Critical Care. He specializes in the management of severe respiratory failure, ECMO and thrombosis. Dr Retter is the only Consultant in the UK to hold dual entry on the specialist register in Intensive Care and Haematology, and provides national guidance on the management of complex haematology patients in critical care. Dr Retter has worked with Volition in an advisory capacity since January 2022 , to help guide the product development and clinical utility of Nu.Q® NETs – a CE-marked routine blood test to detect diseases associated with NETosis, such as sepsis. Cameron Reynolds , President and Group Chief Executive Officer at Volition, said: "We are delighted to
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- VolitionRx Limited (NYSE: VNRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech [Yahoo! Finance]Yahoo! Finance
- Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through AntechPR Newswire
- Antech's breakthrough cancer screening tool launches in Europe, supporting early canine cancer detection [Yahoo! Finance]Yahoo! Finance
- VolitionRx Limited (NYSE: VNRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
VNRX
Earnings
- 11/14/23 - Beat
VNRX
Sec Filings
- 4/26/24 - Form PRE
- 4/26/24 - Form 8-K
- 3/26/24 - Form D
- VNRX's page on the SEC website